House committee approves Stem Cell Therapeutic and Research Reauthorization Act of 2025

The House Committee on Energy and Commerce has approved an amended version of the Stem Cell Therapeutic and Research Reauthorization Act of 2025. This bill would extend the authorization for certain federal programs and research initiatives related to stem cell therapies.

Why it matters: This is primarily an administrative action intended to prevent a lapse in existing research authorizations and programs. It ensures that current stem cell research frameworks remain legally active.

Who it affects

• medical researchers focusing on stem cell therapies

---

This information comes from Congress.gov regarding the House Committee on Energy and Commerce; please consult the official bill text before relying on this summary for legal or professional decisions.

Agency: House
Source: Congress.gov — read the official document